Cannabis Bioscience International Holdings, Inc. (CBIH) EBITDA (2022 - 2026)

Cannabis Bioscience International Holdings has disclosed EBITDA across 5 years of filings, most recently posting -$93259.0 for Q1 2026.

• In Q1 2026, EBITDA rose 27.84% year-over-year to -$93259.0; the TTM figure through Feb 2026 stood at -$398820.0 (down 26.17% YoY), while the FY2025 annual figure was -$421365.0, up 13.32% from the prior year.
• EBITDA came in at -$93259.0 for Q1 2026 at Cannabis Bioscience International Holdings, up from -$95877.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$29634.0 in Q2 2024 to a low of -$284866.0 in Q1 2023.
• Average EBITDA over 5 years is -$134968.4, with a median of -$113419.0 recorded in 2024.
• Year-over-year, EBITDA surged 89.22% in 2024 and slumped 355.22% in 2025.
• Over 5 years, EBITDA stood at -$183608.0 in 2022, then jumped by 48.53% to -$94512.0 in 2023, then soared by 36.91% to -$59627.0 in 2024, then slumped by 60.79% to -$95877.0 in 2025, then grew by 2.73% to -$93259.0 in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$93259.0 in Q1 2026, -$95877.0 in Q4 2025, and -$74784.0 in Q3 2025.